.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The All India Institute of Medical Sciences (AIIMS) and the Indian Space Research Organisation (ISRO) recently signed a landmark agreement to advance space medicine research. This collaboration marks a significant milestone for India’s human spaceflight ambitions. By joining forces, these premier institutions aim to explore how the human body responds to the harsh conditions of space. Consequently, this partnership will create a robust framework for both ground-based and space-based studies.
India is currently pushing boundaries in human spaceflight, which necessitates deeper medical insights. The Human Space Flight Centre (HSFC) and AIIMS will focus on human physiology and cardiovascular regulation. Additionally, they will study musculoskeletal health in microgravity conditions. These areas are critical for ensuring the safety and well-being of astronauts during missions like Gaganyaan.
Interestingly, the insights gained from space studies have profound implications for patients on Earth. Prof K K Deepak, former head of physiology at AIIMS, explained that microgravity induces changes resembling accelerated aging. For instance, astronauts experience significant muscle loss and bone weakening. Therefore, studying these processes helps scientists better understand geriatric conditions.
Furthermore, technologies like leg blood flow devices can treat circulatory problems in the general population. AIIMS Director Prof M Srinivas highlighted that this MoU provides the \"escape velocity\" for medical innovation. He noted that the research would benefit the nation and humankind. ISRO Chairman V. Narayanan also emphasized the importance of such partnerships. Ultimately, this collaboration strengthens India's biomedical research capabilities significantly.
Q1: What are the primary focus areas of the AIIMS-ISRO collaboration?
The partnership focuses on human physiology, cardiovascular regulation, musculoskeletal health in microgravity, and genomics. It also addresses microbiome research and behavioral health for astronauts.
Q2: How does space medicine research benefit patients on Earth?
It provides insights into accelerated aging processes, such as bone density loss and muscle atrophy. This knowledge helps doctors develop better treatments for osteoporosis and circulatory disorders.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
AIIMS and ISRO signed a landmark MoU to collaborate on space medicine research, exploring human physiology in space to enhance medical treatments on Earth....
5 months ago
Diabetic kidney disease remains a major cause of renal failure despite renin-angiotensin system blockade. Learn how combining SGLT2 inhibitors, nonsteroidal MRAs, GLP-1 receptor agonists, and novel aldosterone synthase or endothelin inhibitors addresses residual cardiorenal risk.
Today
A multicenter MPOG database study of 289,047 cesarean delivery cases analyzed adherence to obstetric anesthesia best practices. General anesthesia avoidance reached 97.0%, while post-spinal vasopressor infusions (55.4%) and hypothermia prevention (56.7%) showed the lowest compliance, highlighting key targets.
Yesterday
A comprehensive meta-analysis shows digital health technologies significantly improve 6-minute walk distance and peak oxygen uptake in chronic heart failure patients, highlighting the clinical promise of structured remote cardiac rehabilitation.
Today
Recent research assesses an automated pipeline for CT-based vertebral finite element analysis, revealing how boundary condition components—especially load-point assignment—impact fracture-load accuracy in spinal biomechanics.
Today
A comprehensive analysis of continuous glucose monitoring systems under European Medical Device Regulation 2017/745, examining conformity assessment challenges, Notified Body backlogs, EUDAMED rollout delays, and the critical need for transparent post-market surveillance.
Today
